Biotech Values

[mid_swe]

<<What exactly are you referring to?>>

This educational report was published in November 2002.
All CA4P trials are described from page 16 - 19. On page 18 you have a table with toxicites.

In December 2002, Oxigene announced the ATC phase II trial.
In this trial Oxigene adjusted the treatment regimen and added cardiovascular patient characteristics.
http://clinicaltrials.gov/ct/show/NCT00060242?order=1

In June 2003, received CA4P FDA fast track designation for the treatment of ATC. In July 2003, the FDA awarded orphan drug status to CA4P for the treatment of multiple forms of thyroid cancer including ATC.

In November OXiGENE announced that CA4P will be tested in a trial of newly diagnosed cancer patients whose disease has not yet metastasized. It will be a combination with the chemotherapy drugs doxorubicin/cisplatin and radiation in patients with newly diagnosed anaplastic carcinoma of the thyroid (ATC).

For me this is "evidence" that toxicity is not a big issue. Still, the article is written and published and it makes me a little bit confused.